Drug Profile

ASP 1617

Alternative Names: ASP-1617

Latest Information Update: 02 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Astellas Pharma Global Development
Class Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Systemic lupus erythematosus

Most Recent Events

01 Oct 2021 Discontinued - Phase-I for Systemic lupus erythematosus (In volunteers) in USA (PO), prior to October 2021 (Astellas Pharma pipeline, October 2021)
12 Jun 2021 Astellas Pharma Global Development completes a phase I trial in Systemic lupus erythematosus (In volunteers) in USA (PO) (NCT04077879)
20 Aug 2020 Astellas Pharma re-initiates the phase-I clinical trial in Systemic lupus erythematosus (In volunteers) in USA (PO) (NCT04077879)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com